From clinical cancer research: Rethinking Therapeutic Cancer Vaccine Trials Ongoing therapeutic cancer vaccine trials have yet to show evidence of vaccines spurring a patient's immune system to shrink tumors -- yet patients who receive these vaccines in trials tend to live longer and respond better to subsequent treatment. In the July 1 issue of Clinical [...]
Here it is June 11 and my frustration with the Prostate Cancer Community continues to climb. On May 31, I wrote that the FDA had compromised over the issue of the approval of Provenge. At that time, it was announced that the FDA would be willing to use the interim results of Dendreon’s current, on [...]
Prostate Cancer advocates continue to press the FDA to approve Provenge by staging marches in Washington and Chicago as well as continuing to add their names to Malecare's Action Letter. The advocacy has even caught the attention of the major news services, which have been carrying many stories about the efforts of the prostate community. [...]
Dendreon Corp. has received great news from the FDA about their pending application for the approval of Provenge. STILL TIME TO SIGN PATIENT PETITION TO FDA FOR PROSTATE CANCER TREATMENT APPROVAL and Provengenow news-- Click Here NEW YORK (Dow Jones)--Dendreon Corp. (DNDN) Thursday said the Food and Drug Administration would accept interim trial data to [...]
There are three more day's to put your name forward and sign up to show your support for men with advanced prostate cancer. Even though the Food and Drug Administration is a United States Government agency, it's decisions affect prostate cancer treatment throughout the world. Dr George Cooper has written an excellent letter of understanding [...]